104 related articles for article (PubMed ID: 24967672)
1. The comparative cardiac effects of haloperidol and quetiapine: parsing a review.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2014 Jun; 52(6):23-6. PubMed ID: 24967672
[TBL] [Abstract][Full Text] [Related]
2. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.
Glassman AH; Bigger JT
Am J Psychiatry; 2001 Nov; 158(11):1774-82. PubMed ID: 11691681
[TBL] [Abstract][Full Text] [Related]
3. Torsade de pointes in a patient with complex medical and psychiatric conditions receiving low-dose quetiapine.
Vieweg WV; Schneider RK; Wood MA
Acta Psychiatr Scand; 2005 Oct; 112(4):318-22; author reply 322. PubMed ID: 16156840
[TBL] [Abstract][Full Text] [Related]
4. Incidences, risk factors, and clinical correlates of severe QT prolongation after the use of quetiapine or haloperidol.
Wang CL; Wu VC; Lee CH; Wu CL; Chen HM; Huang YT; Chang SH
Heart Rhythm; 2024 Mar; 21(3):321-328. PubMed ID: 38231170
[TBL] [Abstract][Full Text] [Related]
5. QTc prolongation, torsades de pointes, and psychotropic medications.
Beach SR; Celano CM; Noseworthy PA; Januzzi JL; Huffman JC
Psychosomatics; 2013; 54(1):1-13. PubMed ID: 23295003
[TBL] [Abstract][Full Text] [Related]
6. Risk management of QTc-prolongation in patients receiving haloperidol: an epidemiological study in a University hospital in Belgium.
Vandael E; Vandenberk B; Vandenberghe J; Spriet I; Willems R; Foulon V
Int J Clin Pharm; 2016 Apr; 38(2):310-20. PubMed ID: 26749342
[TBL] [Abstract][Full Text] [Related]
7. Torsade de pointes associated with the administration of intravenous haloperidol:a review of the literature and practical guidelines for use.
Hassaballa HA; Balk RA
Expert Opin Drug Saf; 2003 Nov; 2(6):543-7. PubMed ID: 14585064
[TBL] [Abstract][Full Text] [Related]
8. Accuracy of uncorrected versus corrected QT interval for prediction of torsade de pointes associated with intravenous haloperidol.
Tisdale JE; Kovacs R; Mi D; McCabe GP; Cariera BL; Sharma N; Rosman H
Pharmacotherapy; 2007 Feb; 27(2):175-82. PubMed ID: 17253907
[TBL] [Abstract][Full Text] [Related]
9. Torsade de pointes following intravenous haloperidol administration in a patient with complete heart block.
Ginwalla M; Biblo LA; Paydak H
WMJ; 2009 Feb; 108(1):48-50. PubMed ID: 19326637
[TBL] [Abstract][Full Text] [Related]
10. Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature.
Lawrence KR; Nasraway SA
Pharmacotherapy; 1997; 17(3):531-7. PubMed ID: 9165555
[TBL] [Abstract][Full Text] [Related]
11. Agreement between ICU clinicians and electrophysiology cardiologists on the decision to initiate a QTc-interval prolonging medication in critically ill patients with potential risk factors for torsade de pointes: a comparative, case-based evaluation.
Fongemie JM; Al-Qadheeb NS; Estes NA; Roberts RJ; Temtanakitpaisan Y; Ruthazer R; Devlin JW
Pharmacotherapy; 2013 Jun; 33(6):589-97. PubMed ID: 23529904
[TBL] [Abstract][Full Text] [Related]
12. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V;
Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
[TBL] [Abstract][Full Text] [Related]
13. Torsade de pointes and low-dose oral haloperidol.
Jackson T; Ditmanson L; Phibbs B
Arch Intern Med; 1997 Sep; 157(17):2013-5. PubMed ID: 9308514
[TBL] [Abstract][Full Text] [Related]
14. [Cardiovascular risk of haloperidol vs. atypical anti-psychotic drugs in schizophrenia treatment].
Dobrin I; Dobrin RP; Chele G; Stefănescu C; Knieling A; Chiriţă R
Rev Med Chir Soc Med Nat Iasi; 2010; 114(3):658-61. PubMed ID: 21243790
[TBL] [Abstract][Full Text] [Related]
15. Assessment of Safety Margin of an Antipsychotic Drug Haloperidol for Torsade de Pointes Using the Chronic Atrioventricular Block Dogs.
Izumi-Nakaseko H; Nakamura Y; Cao X; Wada T; Ando K; Sugiyama A
Cardiovasc Toxicol; 2017 Jul; 17(3):319-325. PubMed ID: 27738880
[TBL] [Abstract][Full Text] [Related]
16. Torsade de pointes associated with the administration of intravenous haloperidol.
Hassaballa HA; Balk RA
Am J Ther; 2003; 10(1):58-60. PubMed ID: 12522522
[TBL] [Abstract][Full Text] [Related]
17. Psychiatric medications and sudden cardiac death: putting the risk in perspective.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2015 Feb; 53(2):23-5. PubMed ID: 25654571
[TBL] [Abstract][Full Text] [Related]
18. Comparative safety of antipsychotics in the WHO pharmacovigilance database: the haloperidol case.
Meyer-Massetti C; Vaerini S; Rätz Bravo AE; Meier CR; Guglielmo BJ
Int J Clin Pharm; 2011 Oct; 33(5):806-14. PubMed ID: 21809143
[TBL] [Abstract][Full Text] [Related]
19. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond?
Meyer-Massetti C; Cheng CM; Sharpe BA; Meier CR; Guglielmo BJ
J Hosp Med; 2010 Apr; 5(4):E8-16. PubMed ID: 20394022
[TBL] [Abstract][Full Text] [Related]
20. Schizophrenia, antipsychotic drugs, and cardiovascular disease.
Glassman AH
J Clin Psychiatry; 2005; 66 Suppl 6():5-10. PubMed ID: 16107178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
